India to Afghanistan: Alprazolam Export Trade Route

To import Alprazolam formulations into Afghanistan, the following approvals and registrations are necessary:

• Application Submission: A comprehensive application must be submitted, including a cover letter on the distributor's official letterhead and a completed application form, both signed and stamped.

• Manufacturer Authorization: An authorization letter from the manufacturer, valid for at least five years, permitting import, distribution, registration, and marketing. This letter should be on the manufacturer's original letterhead and signed by the company president or deputy.

• Regulatory Certificates:
• Manufacturing License: A copy of the manufacturer's valid manufacturing license.
• Certificate of Pharmaceutical Product (CoPP): Endorsed by the Ministry of Health, Ministry of Commerce, and Ministry of Foreign Affairs in the country of origin, and further endorsed by the Afghanistan Embassy.
• Good Manufacturing Practice (GMP) Certificate: A copy of the GMP certificate, duly endorsed.

• Product Documentation:
• Product Registration Certificate: Evidence of product registration in at least one other country.
• Product Labeling and Patient Information Leaflet: Complete and compliant with regulatory language and format guidelines.

• Technical Requirements:
• Active Pharmaceutical Ingredient (API) Information: Details of the API manufacturing site, synthesis route, certificates of analysis for at least two batches, container closure system, stability data, and GMP certificate of the API manufacturer.
• Finished Pharmaceutical Product Details: Description of the formulation, pharmaceutical development information, in-vitro dissolution or drug release studies, manufacturing procedures, certificates of analysis for excipients and at least three batches of the finished product, container closure system details, and stability studies for at least three batches.

• Local Representation: Appointment of a locally authorized representative responsible for post-marketing surveillance, adverse event reporting, product recalls, and regulatory communication.

The dossier should be compiled in the Common Technical Document (CTD) format. While specific timelines for approval and product registration fees are not publicly disclosed, applicants should anticipate a thorough evaluation process. Additionally, the NDRA may require GMP inspections of Indian manufacturing facilities to ensure compliance with international quality standards.

Indian exporters of Alprazolam formulations must adhere to stringent GMP standards to supply products to Afghanistan:

• GMP Certification: Manufacturers must possess a valid GMP certificate, endorsed by the relevant authorities, confirming compliance with international quality standards.

• Regulatory Compliance: Facilities should align with the updated Schedule M of the Drugs and Cosmetics Act, which was revised in December 2023 to harmonize with WHO-GMP standards. The deadline for compliance was set for December 31, 2025. Non-compliance beyond this date may result in operational shutdowns.

• Inspection History: As of December 2025, the USFDA conducted 212 inspections of Indian drug facilities, with 'official action indicated' (OAI) cases dropping to 11 from 20 in the previous year. This indicates an improvement in compliance, though vigilance remains essential.

• Recent Regulatory Actions: In 2024 and 2025, several Indian pharmaceutical companies faced regulatory actions due to GMP violations, including issues like cross-contamination, data integrity lapses, and inadequate quality systems. Notable cases include Granules India, Eugia Pharma Specialties, and Sun Pharma's Halol facility.

Several regulatory changes and policy shifts have impacted Indian pharmaceutical exports to Afghanistan in the past 18 months:

• Schedule M Amendment: In December 2023, India's Ministry of Health and Family Welfare revised Schedule M of the Drugs and Cosmetics Act to align with WHO-GMP standards. This amendment mandated stronger quality controls across manufacturing processes to enhance drug safety and prevent adulteration.

• Compliance Deadlines: The deadline for compliance with the revised Schedule M was set for December 31, 2025. Non-compliant manufacturers faced potential closure post this date. This move aimed to ensure that all pharmaceutical companies, including Micro, Small, and Medium Enterprises (MSMEs), adhere to global quality standards.

• Regulatory Crackdown: In November 2025, the Drugs Controller General of India (DCGI) directed state authorities to enforce updated GMP rules strictly. States like Delhi, Himachal Pradesh, and Uttarakhand initiated actions against non-compliant manufacturers, issuing warning notices and planning inspections to ensure adherence to the new standards.

These developments underscore the importance of compliance with international GMP standards for Indian pharmaceutical exporters aiming to supply products to Afghanistan.

As of 2024, Afghanistan's market for alprazolam formulations is estimated to be approximately $0.6 million USD. This demand is primarily driven by the prevalence of anxiety and panic disorders within the population. The country's healthcare infrastructure is heavily reliant on imports due to limited domestic pharmaceutical manufacturing capabilities. Consequently, the majority of alprazolam formulations are imported, with India being a significant supplier.

Afghanistan imposes a 2.5% import duty on pharmaceutical products classified under HS code 30049088. In addition to the import duty, a Value Added Tax (VAT) of 10% is applied to the import value. There are no existing Free Trade Agreements (FTAs) between Afghanistan and India that provide preferential tariff rates for pharmaceutical imports. Furthermore, there are no anti-dumping duties currently imposed on alprazolam formulations imported into Afghanistan.

India is the predominant supplier of alprazolam formulations to Afghanistan, accounting for approximately 3.8% of India's total exports of these products, valued at $16.6 million USD. Other countries, such as China and various European Union member states, also export pharmaceutical products to Afghanistan, but their share in the alprazolam segment is comparatively smaller. Indian manufacturers are known for offering competitive pricing, which, combined with established trade routes and regulatory approvals, positions India as a leading supplier in this market.

India is a global leader in the production of generic pharmaceuticals, accounting for approximately 60% of the world's solid oral dosage forms as of 2024. This extensive manufacturing capacity enables the efficient production of Alprazolam formulations, including tablets and capsules. The country's cost-effective production is attributed to economies of scale, a skilled workforce, and a well-established supply chain. As of 2024, India hosts 396 facilities approved by the U.S. Food and Drug Administration (FDA), encompassing both Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDF) manufacturing. This regulatory compliance underscores India's capability to produce high-quality Alprazolam formulations that meet stringent international standards.

When comparing Alprazolam formulations from India, China, and the European Union (EU), several factors emerge:

• Cost: Indian manufacturers offer Alprazolam formulations at competitive prices due to lower production costs and economies of scale. Chinese generic formulations are also cost-effective; however, concerns about manufacturing quality have been noted. EU-branded generics are typically priced higher, reflecting stringent regulatory standards and higher production costs.

• Quality Perception: Indian pharmaceutical companies have a strong reputation for adhering to international quality standards, with numerous facilities approved by the FDA and other regulatory bodies. Chinese manufacturers have faced scrutiny over quality concerns, impacting their global perception. EU manufacturers are renowned for high-quality products, albeit at a premium price point.

• Regulatory Acceptance in Afghanistan: Afghanistan's regulatory framework recognizes and accepts pharmaceutical imports from India, facilitating smoother market entry for Indian Alprazolam formulations. Imports from China and the EU are also accepted but may require more rigorous documentation and compliance checks.

• Supply Reliability: Indian manufacturers have a proven track record of reliable supply chains, supported by robust infrastructure and regulatory compliance. Chinese suppliers have experienced disruptions due to regulatory interventions and quality issues. EU suppliers maintain consistent quality but may face longer lead times and higher costs.

The India-Afghanistan supply chain for Alprazolam formulations is characterized by:

• Manufacturing Capacity: India's extensive pharmaceutical manufacturing infrastructure ensures ample capacity for producing Alprazolam formulations. Companies like Sun Pharma are investing in new facilities to enhance production capabilities.

• Packaging and Cold Chain Capabilities: Indian manufacturers possess advanced packaging facilities and cold chain logistics, ensuring product stability and compliance with international standards.

• Regulatory Compliance: Indian pharmaceutical companies maintain a strong compliance record with international regulatory bodies, including the FDA and WHO, ensuring consistent product quality and safety.

• Capacity Constraints and Expansion Plans: While current capacity meets demand, leading manufacturers are proactively expanding facilities to accommodate future growth and mitigate potential constraints. For instance, Sun Pharma's investment in a new formulations manufacturing facility in Madhya Pradesh aims to bolster production capacity.

For Afghan buyers sourcing Alprazolam formulations from India, the following strategies are recommended:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to diversify supply sources, reducing dependency on a single supplier and enhancing supply chain resilience.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and cash flow.

• Payment Terms: Establish clear payment terms, such as letters of credit or advance payments, to build trust and ensure timely transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet regulatory standards and quality expectations.

• Regulatory Compliance: Ensure that selected suppliers have the necessary approvals from international regulatory bodies, such as the FDA and WHO, to guarantee product quality and facilitate smoother import processes.

By meticulously following these guidelines, Afghan pharmaceutical companies can establish reliable partnerships with Indian suppliers, ensuring the consistent quality and safety of Alprazolam formulations imported into Afghanistan.